Last reviewed · How we verify
fostair
fostair is a Small molecule drug developed by Hull University Teaching Hospitals NHS Trust. It is currently in Phase 2 development. Also known as: beclometasone dipropionate and formoterol fumarate.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | fostair |
|---|---|
| Also known as | beclometasone dipropionate and formoterol fumarate |
| Sponsor | Hull University Teaching Hospitals NHS Trust |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate) (PHASE3)
- A Study Comparing the Effects of Trimbow to Fostair in COPD (PHASE4)
- Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis (PHASE2)
- Beta Blocker Therapy in Moderate to Severe COPD (PHASE4)
- Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation (PHASE3)
- Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management
- Qvar Versus Clenil, a General Practice Research Database Study
- Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fostair CI brief — competitive landscape report
- fostair updates RSS · CI watch RSS
- Hull University Teaching Hospitals NHS Trust portfolio CI
Frequently asked questions about fostair
What is fostair?
Who makes fostair?
Is fostair also known as anything else?
What development phase is fostair in?
Related
- Manufacturer: Hull University Teaching Hospitals NHS Trust — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: beclometasone dipropionate and formoterol fumarate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing